triamcinolone acetonide has been researched along with Diabetic Neuropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, J; Jiang, YR; Qu, JF | 1 |
| Al-Haddad, CE; Bashshur, ZF; Jurdi, FA | 1 |
2 other study(ies) available for triamcinolone acetonide and Diabetic Neuropathies
| Article | Year |
|---|---|
Resolution of diabetic papillopathy with a single intravitreal injection of bevacizumab combined with triamcinolone acetonide.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Glucocorticoids; Humans; Intravitreal Injections; Male; Optic Disk; Papilledema; Tomography, Optical Coherence; Triamcinolone Acetonide | 2013 |
Intravitreal triamcinolone acetonide for the management of diabetic papillopathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fluorescein Angiography; Glucocorticoids; Humans; Injections; Intraocular Pressure; Male; Middle Aged; Papilledema; Triamcinolone Acetonide; Visual Acuity; Vitreous Body | 2004 |